**专家谈青光眼防治：致盲不可逆，个性化诊疗提升治疗效果**
近日，一场由艾伯维支持的2024年眼科国际交流会在广州成功举办。全球约300位医疗卫生领域的专业讲者和参会专家汇聚一堂，共同探讨创新眼科管理治疗、个性化患者诊疗、以及眼科护理整合三大主题。会议聚焦于两大不可逆致盲性疾病——青光眼与眼底病的防治，旨在推动全球眼科医疗技术与诊疗观念的进步，以“全球智慧”助力中国眼健康事业的发展。
**青光眼防治：挑战与突破**
北京同仁眼科中心主任、首都医科大学眼科学院院长王宁利教授在会上指出，中国青光眼患者数量高达2600万，但诊断率仅为10%至20%。青光眼一年造成的国民经济损失达到9580多亿元，占GDP的1.8%。王宁利教授强调，虽然青光眼是导致失明的第一位不可逆性眼病，但通过早期干预，可以显著减少终生失明病例，这也是国家积极推进的重要工作之一。
王宁利教授进一步指出，青光眼的治疗主要依赖于药物、激光和手术等手段，其中药物治疗的比例仅为30%左右，激光治疗的使用率更低，手术治疗则占到65%至70%。对于眼压正常但视神经仍在退化的青光眼患者，以及眼压正常但仍有青光眼风险的患者，个性化诊疗显得尤为重要。通过精确的诊断细分领域，医生可以实施更为精准的治疗，从而提高治疗效果。
**个性化诊疗：提升治疗效果的关键**
会议中，专家们强调了个性化诊疗在青光眼治疗中的重要性。王宁利教授提到，青光眼是一个复杂的疾病，涉及多种类型，如眼压高的、眼压不高的、房角关闭的、房角开放的、先天的、后天的以及继发的。对于这类疾病，精准的诊断和细分领域治疗是关键，可以显著提升治疗效果，实现精准“打靶”，达到更好的治疗效果。
在青光眼手术技术方面，微创手术的应用越来越广泛，其特点是创伤小、恢复快，不仅对患者有益，也提高了医生的工作效率。青光眼引流管赞宜®(XEN®)作为创新代表，通过真实世界证据辅助临床评价，成为首个在中国获批的微创引流管，为青光眼手术带来了革命性的变革，将创伤性手术转变为极小创伤的微创手术，仅需一个注射器即可完成手术，极大地提升了手术的安全性和便利性。
**总结**
通过本次交流会，全球眼科专家共同探讨了青光眼等致盲性眼病的防治策略，强调了个性化诊疗在提升治疗效果中的重要性。随着新技术的不断应用和创新，眼科医疗领域有望实现更大的突破，为患者提供更为精准、高效的治疗方案，助力中国乃至全球的眼健康事业向前发展。
英语如下：
**Personalized Treatment Elevates Glaucoma Management, Experts Discuss Global Eye Health Advances**
In a successful 2024 International Ophthalmology Exchange Conference, supported by AbbVie, approximately 300 experts and speakers from the healthcare sector convened in Guangzhou. The event focused on three key themes: innovative ophthalmic management, personalized patient care, and the integration of ophthalmic nursing, all aimed at advancing global ophthalmic medical technology and treatment concepts, leveraging global expertise to propel China’s eye health initiatives.
**Glaucoma Prevention and Control: Challenges and Breakthroughs**
Professor Wang Ningli, Director of the Ophthalmology Center at Beijing Tongren Hospital and Dean of the Eye Science College at Capital Medical University, highlighted the challenges and breakthroughs in glaucoma prevention and control. With an estimated 26 million glaucoma patients in China, the diagnosis rate is as low as 10% to 20%. The annual economic loss due to glaucoma amounts to over 958 billion yuan, accounting for 1.8% of GDP. Professor Wang emphasized that, as the leading irreversible cause of blindness, early intervention can significantly reduce cases of permanent blindness, making it a critical focus of national efforts.
Professor Wang further explained that glaucoma treatment mainly relies on drugs, laser, and surgery, with drug treatment accounting for only about 30% of cases, lower usage of laser therapy, and surgical treatment comprising 65% to 70%. For patients with glaucoma who have normal eye pressure but deteriorating optic nerve, or those with normal eye pressure but still at risk of glaucoma, personalized treatment becomes particularly crucial. Precise diagnosis and treatment in specific fields enable doctors to implement more accurate therapies, thereby enhancing treatment outcomes.
**Personalized Treatment: Key to Improving Treatment Effectiveness**
During the conference, experts underscored the significance of personalized treatment in glaucoma management. Professor Wang mentioned that glaucoma is a complex disease, involving various types such as high-pressure, low-pressure, angle-closure, angle-opening, congenital, acquired, and secondary. For such diseases, accurate diagnosis and treatment in specific fields are essential, significantly improving treatment effectiveness and achieving precise “targeting” for better outcomes.
Regarding glaucoma surgical techniques, minimally invasive surgery is increasingly being applied, characterized by minimal trauma and rapid recovery, benefiting both patients and enhancing the efficiency of doctors. The XEN® Minimally Invasive Glaucoma Stent, as a representative of innovative solutions, has revolutionized glaucoma surgery with real-world evidence supporting its clinical evaluation, becoming the first minimally invasive drainage tube approved in China. This has transformed traumatic surgeries into minimally invasive procedures, requiring only an injection, greatly enhancing surgical safety and convenience.
**Summary**
Following the conference, global ophthalmologists collectively discussed strategies for preventing and controlling blinding eye diseases like glaucoma, emphasizing the importance of personalized treatment in elevating treatment outcomes. With the continuous application and innovation of new technologies, the ophthalmic medical field is poised for significant advancements, offering patients more precise and efficient treatment options, driving forward China’s and the global eye health initiatives.
【来源】http://www.chinanews.com/life/2024/07-22/10255255.shtml
Views: 1